<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2301244786
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Deroxi Liposomal
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DOXORUBICIN HYDROCHLORIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Concentrate for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        18
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1493.05
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Natco Pharma Limited" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Natco Pharma Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2272]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SUDAIR PHARMA COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SUDAIR PHARMA COMPANY
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01DB01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Deroxi Liposomal is an antitumour agent.</p><p>Deroxi Liposomal is used to treat cancer of the breast in patients at risk for heart problems.</p><p>Deroxi Liposomal is also used to treat cancer of the ovary. It is used to kill cancer cells, shrink the size of the tumour, delay the growth of the tumour, and extend your survival.</p><p>Deroxi Liposomal is also used in combination with another medicine, bortezomib, to treat multiple myeloma (a cancer of the blood) in patients who have received at least 1 prior therapy.</p><p>Deroxi Liposomal is also used to produce an improvement in your Kaposi&rsquo;s sarcoma including flattening, lightening and even shrinkage of the cancer. Other symptoms of Kaposi&rsquo;s sarcoma, such as swelling around the tumour, may also improve or disappear.</p><p>Deroxi Liposomal contains a medicine which is able to interact with cells in such a way as to selectively kill cancer cells. The doxorubicin hydrochloride in Deroxi Liposomal is enclosed in tiny spheres called pegylated liposomes which help to deliver the medicinal product from the blood stream to the cancerous tissue rather than healthy normal tissue.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Deroxi Liposomal</strong></p><p>- if you are allergic to doxorubicin hydrochloride, peanut or soya, or any of the ingredients of this medicine (listed in section 6).</p><p><strong>Warnings and precautions</strong></p><p>You should tell your doctor about any of the following:</p><p>- if you are receiving any treatment for heart disease or liver disease;</p><p>- if you are diabetic, because Deroxi Liposomal contains sugar which may require an adjustment to the treatment of your diabetes;</p><p>- if you have Kaposi&rsquo;s sarcoma and have had your spleen removed;</p><p>- if you notice sores, discolouration or any discomfort in your mouth.</p><p><strong>Children and adolescents</strong></p><p>Deroxi Liposomal should not be used in children and adolescents, because it is not known how the medicine will affect them.</p><p><strong>Other medicines and Deroxi Liposomal</strong></p><p><strong>Tell your doctor or pharmacist</strong></p><p>- if you are taking or have recently taken any other medicines, including medicines obtained without a prescription;</p><p>- about any other cancer treatments you are on or have been taking, as particular care needs to be taken with treatments which reduce the number of white blood cells, as this may cause further reduction in the number of white blood cells. If you are unsure about what treatments you have received or any illnesses you have had, discuss these with your doctor.</p><p><strong>Pregnancy and breast-feeding</strong></p><p>Ask your doctor or pharmacist for advice before taking any medicine.</p><p>Because the active ingredient doxorubicin hydrochloride in Deroxi Liposomal may cause birth defects, it is important to tell your doctor if you think you are pregnant. Avoid becoming pregnant while you or your partner are taking Deroxi Liposomal and in the six months following discontinuation of Deroxi Liposomal treatment.</p><p>Because doxorubicin hydrochloride may be harmful to nursing infants, women must discontinue breast-feeding before starting treatment with Deroxi Liposomal. Health experts recommend that HIV infected women do not breast-feed their infants under any circumstances in order to avoid transmission of HIV.</p><p><strong>Driving and using machines</strong></p><p>Do not drive or use any tools or machines if you feel tired or sleepy from treatment with Deroxi Liposomal.</p><p><strong>Deroxi Liposomal </strong><strong>contains soya oil and sodium</strong></p><p>Deroxi Liposomal contains soya oil. If you are allergic to peanut or soya, do not use this medicine. Deroxi Liposomal contains less than 1 mmol sodium (23 mg) per dose, that is to say &lsquo;essentially sodium-free.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Deroxi Liposomal is a unique formulation. It must not be used interchangeably with other formulations of doxorubicin hydrochloride.</p><p><strong>How much Deroxi Liposomal is given</strong></p><p>If you are being treated for breast cancer or ovarian cancer, Deroxi Liposomal will be administered at a dose of 50 mg per square metre of your body surface area (based on your height and weight). The dose is repeated every 4 weeks for as long as the disease does not progress and you are able to tolerate the treatment.</p><p>If you are being treated for multiple myeloma, and have already received at least 1 prior therapy, Deroxi Liposomal will be administered at a dose of 30 mg per square metre of your body surface area (based on your height and weight) as a 1 hour intravenous infusion on day 4 of the bortezomib 3 week regimen immediately after the bortezomib infusion. The dose is repeated as long as you respond satisfactorily and tolerate treatment.</p><p>If you are being treated for Kaposi&rsquo;sarcoma, Deroxi Liposomal will be administered at a dose of 20 mg per square metre of your body surface area (based on your height and weight). The dose is repeated every 2 to 3 weeks for 2-3 months, then as often as necessary to maintain an improvement in your condition.</p><p><strong>How&nbsp;Deroxi Liposomal is given</strong></p><p>Deroxi Liposomal will be given to you by your doctor in a drip (infusion) into a vein. Depending on the dose and indication, this may take from 30 minutes to more than one hour (i.e., 90 minutes).</p><p><strong>If you use more Deroxi Liposomal than you should</strong></p><p>Acute overdosing worsens side effects like sores in the mouth or decreases the number of white blood cells and platelets in the blood. Treatment will include administration of antibiotics, platelet cell transfusions, use of factors which stimulate production of white blood cells and symptomatic treatment of mouth sores.</p><p>If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>During the infusion of Deroxi Liposomal, the following reactions may occur:</p><p>- severe allergic reaction that may include a swollen face, lips, mouth, tongue or throat; difficulty swallowing or breathing; itchy rash (hives)</p><p>- inflamed and narrowed airways in the lungs, causing coughing, wheezing and shortness of breath (asthma)</p><p>- flushing, sweating, chills or a fever</p><p>- chest pain or discomfort</p><p>- back pain</p><p>- high or low blood pressure</p><p>- fast heart beat</p><p>- fits (seizures)</p><p>Leaking of the injection fluid from the veins into the tissues under the skin may occur. If the drip stings or hurts while you are receiving a dose of Deroxi Liposomal, tell your doctor immediately.</p><p>Your doctor should be contacted immediately if any of the following serious side effects are noticed:</p><p>- you develop fever, feel tired, or if you have signs of bruising or bleeding (very common)</p><p>- redness, swelling, peeling or tenderness, mainly on the hands or feet (&lsquo;hand-foot&rsquo; syndrome).</p><p>These effects have been seen very commonly and are sometimes severe. In severe cases, these effects may interfere with certain daily activities, and may last for 4 weeks or longer before resolving completely. The doctor may wish to delay the start and/or reduce the dose of the next treatment (see Strategies to prevent and treat hand foot syndrome, below)</p><p>- sores in mouth, severe diarrhoea or vomiting or nausea (very common)</p><p>- infections (common), including lung infections (pneumonia) or infections that may affect your vision</p><p>- being short of breath (common)</p><p>- severe stomach pain (common)</p><p>- severe weakness (common)</p><p>- severe allergic reaction that may include a swollen face, lips, mouth, tongue or throat; difficulty swallowing or breathing; itchy rash (hives) (uncommon)</p><p>- cardiac arrest (heart stops beating); heart failure, in which the heart does not pump enough blood to the rest of the body, which makes you short of breath and may lead to swollen legs (uncommon)</p><p>- blood clot that moves to the lungs, causes chest pain and makes you short of breath (uncommon)</p><p>- swelling, warmth, or tenderness in the soft tissues of your leg, sometimes with pain which gets worse when you stand or walk (rare)</p><p>- severe or life-threatening rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals (Stevens-Johnson syndrome) or over most of the body (toxic epidermal necrolysis) (rare)</p><p><strong>Other side effects</strong></p><p>Between infusions, the following may occur:</p><p><strong>Very common side effects (may affect more than 1 in 10 people)</strong></p><p>- decrease in the number of white blood cells, which can increase the chances of infections. In</p><p>rare cases, having low white blood cells may lead to severe infection. Anaemia (reduction in red blood cells) may cause tiredness, and decreased platelets in the blood may increase the risk of bleeding. It is because of the potential changes in your blood cells that you will have regular blood tests.</p><p>- decreased appetite;</p><p>- constipation;</p><p>- skin rashes, including redness of the skin, allergic skin rash, red or raised rash on the skin</p><p>- hair loss</p><p>- pain including in the muscles and chest muscle, joint, arm, or leg</p><p>- feeling very tired</p><p><strong>Common side effects (may affect up to 1 in 10 people)</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infections, including severe infection throughout the body (sepsis), lung infections, herpes zoster virus infections (shingles), a type of bacterial infection (mycobacterium avium complex infection), urinary tract infection, fungal infections (including thrush and oral thrush in the mouth) infection of the hair roots, infected or irritated throat, infected nose, sinuses or throat (cold)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low number of a type of white blood cell (neutrophils), with a fever</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe weight loss and muscle wasting, not enough water in the body (dehydration), low level of potassium, sodium, or calcium in the blood</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling confused, feeling anxious, depression, difficulty sleeping</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nerve damage that may cause tingling, numbness, pain or loss of pain sensation, nerve pain, unusual feeling in the skin (such as tingling or a crawling feeling), decreased feeling or sensitivity, especially in the skin</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; change in sense of taste, headache, feeling very sleepy with low energy, feeling dizzy;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflamed eyes (conjunctivitis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fast heart beat</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high or low blood pressure, flushing</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath that may be brought on by physical activity, nose bleeds, cough</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflamed stomach lining or foodpipe, ulcers (sores) in the mouth, indigestion, difficulty swallowing, mouth pain, dry mouth</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin problems, including flaky or dry skin, redness of the skin, blister or ulcer (sore) on the skin, itching, dark skin patches</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; excessive sweating</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle spasms or aches</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain including in the muscles, bone, or back</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain when passing urine</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reaction to infusion of the medicine, flu-like illness, chills, inflamed lining of the cavities and passages in the body, such as the nose, mouth or windpipe, feeling weak, generally feeling unwell, swelling caused by fluid build up in the body, swollen hands, ankles or feet</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight loss</p><p>When Deroxi Liposomal is used alone, some of these effects are less likely to occur, and some have not occurred at all.</p><p><strong>Uncommon side effects (may affect up to 1 in 100 people)</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; herpes simplex virus infections (cold sores or genital herpes), fungal infection</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low number of all types of blood cells, increased number of &lsquo;platelets&rsquo; (cells that help blood to clot)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reaction</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high level of potassium in the blood, low level of magnesium in the blood</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nerve damage affecting more than one area of the body</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fits (seizures), fainting</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; unpleasant or painful sensation, especially to touch, feeling sleepy</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blurred vision, watery eyes</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart beat feels fast or uneven (palpitations), heart muscle disease, heart damage</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tissue damage (necrosis) where the injection is given, inflamed veins that cause swelling and pain, feeling dizzy upon sitting up or standing up</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest discomfort</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; passing wind, inflamed gums (gingivitis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin problems or rashes, including flaky or peeling skin, allergic skin rash, ulcer (sore) or hives on the skin, discoloured skin, change in the natural colour (pigment) of the skin, small red or purple spots caused by bleeding under the skin, nail problems, acne</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle weakness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; breast pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; irritation or pain where the injection is given</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swollen face, high body temperature</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; symptoms (such as inflammation, redness or pain) come back at a part of the body that previously received radiation therapy or was previously damaged by a chemotherapy injection into a vein</p><p><strong>Rare side effects (may affect up to 1 in 1,000 people)</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infection that occurs in people with a weak immune system</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low number of blood cells made in the bone marrow</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflamed retina, which may cause changes in vision or blindness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal heart rhythm, abnormal heart tracing on an ECG (electrocardiogram) and may be with a slow heart beat, problem with the heart that affects the heart beat and rhythm, blue colour to the skin and mucosa caused by low oxygen in the blood</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; widening of blood vessels</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tight feeling in the throat</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sore and swollen tongue, ulcer (sore) on the lip</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rash with fluid-filled blisters</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vaginal infection, redness of the scrotum</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; problems with the lining of the cavities and passages in the body, such as the nose, mouth or windpipe</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal liver blood test results, increased level of &lsquo;creatinine&rsquo; in the blood</p><p><strong>Not known (frequency cannot be estimated from the available data)</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cancer of the blood that develops quickly and affects the blood cells (acute myeloid leukaemia), bone marrow disease that affects the blood cells (myelodysplastic syndrome), cancer of the mouth or lip.</p><p><u>Strategies to prevent and treat hand-foot syndrome include:</u></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; soaking hands and/or feet in basins of cold water when possible (e.g., while watching television, reading, or listening to the radio);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; keeping hands and feet uncovered (no gloves, socks, etc.);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; staying in cool places;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; taking cool baths during hot weather;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; avoiding vigorous exercise that might cause trauma to the feet (e.g., jogging);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; avoiding exposure of skin to very hot water (e.g., jacuzzis, saunas);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; avoiding tight fitting footwear or high-heeled shoes.</p><p>Pyridoxine (Vitamin B6):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vitamin B6 is available without prescription;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; take 50-150 mg daily beginning at the first signs of redness or tingling</p><p>Reporting of side effects<strong>&nbsp;</strong></p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your &lt;doctor, health care provider&gt; &lt;or&gt; &lt;pharmacist&gt;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Store in a refrigerator (2&deg;C &ndash; 8&deg;C). Do not freeze.</p><p><strong>After dilution:</strong></p><p>Chemical and physical in-use stability has been demonstrated for 24 hours at 2&deg;C to 8&deg;C.</p><p>From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and should not be longer than 24 hours at 2&deg;C to 8&deg;C. Partially used vials must be discarded.</p><p>Do not use this medicine after the expiry date which is stated on the label and carton.</p><p>Do not use this medicine if you notice that it shows evidence of precipitation or any other particulate matter.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>10 ml/20mm Type I transparent tubular glass vial stoppered with 20mm grey bromobutyl rubber stopper and sealed with 20 mm flip off seal.<br />Supplied as a single pack.<br />30 mL/20mm USP Type I transparent tubular glass vial stoppered with 20mm grey bromobutyl rubber stopper and sealed with 20 mm flip off seal.<br />Supplied as a single pack.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                10 ml/20mm Type I transparent tubular glass vial stoppered with 20mm grey bromobutyl rubber stopper and sealed with 20 mm flip off seal.
Supplied as a single pack.
30 mL/20mm USP Type I transparent tubular glass vial stoppered with 20mm grey bromobutyl rubber stopper and sealed with 20 mm flip off seal.
Supplied as a single pack.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>MARKETING AUTHORIZATION HOLDER: </strong></p><p>Sudair Pharma Company (SPC)</p><p>King Fahad Road, building 8006- 4th Floor Riyadh, Saudi Arabia</p><p>Tel: +966-11-920001432</p><p>Fax: +966-11-4668195</p><p>Email: info@sudairpharma.com</p><p>Mailing: P.O. Box 12363 Riyadh, Saudi Arabia</p><p>&nbsp;</p><p><strong>Manufacturer:</strong></p><p>Natco Pharma Ltd.</p><p>Pharma Division, Unit-V Kothur,</p><p>Rangareddy District, Telangana - 509 228,</p><p>INDIA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                03/2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ديروكسي ليبوزومال هو دواء من فئة مضادات الأورام.</p><p dir="RTL">يُستخدم ديروكسي ليبوزومال لعلاج سرطان الثدي عند المرضى المعرضين لخطر حدوث مشاكل في القلب.</p><p dir="RTL">كما يُستخدم ديروكسي ليبوزومال لعلاج سرطان المبيض؛ حيث يُستخدم لقتل الخلايا السرطانية، وتقليل حجم الورم، وتأخير نمو الورم، وتوسيع مجال الشفاء.</p><p dir="RTL">يُستخدم ديروكسي ليبوزومال أيضًا مع عقار آخر هو بورتيزوميب؛ لعلاج الورم النقوي (النخاعي) المُتعدِّد للمرضى الذين تلقوا علاجًا واحدًا سابقًا على الأقل.</p><p dir="RTL">كما يُستخدم ديروكسي ليبوزومال لإحداثِ تحسُّنٍ في مرض ساركوما كابوزي، بما في ذلك تسطيح الورم السرطاني وتخفيفه وحتى انكماشه. كما يمكن أن يؤدي أيضًا إلى تحسُّن أعراض أخرى لمرض ساركوما كابوزي، كتقليل أو اختفاء الانتفاخ حول الورم.</p><p dir="RTL">يحتوي ديروكسي ليبوزومال على مادة فعالة يمكنها التفاعل مع الخلايا بطريقة تقتل الخلايا السرطانية بشكلٍ انتقائي. إن مادة دوكسوروبيسين هيدروكلوريد الفعالة الموجودة في ديروكسي ليبوزومال مغلفة في كريات صغيرة تُسمى حويصلات ممتدة التأثير تُساعد في توصيل المادة الدوائية من مجرى الدم إلى النسيج السرطاني بدلًا من النسيج السليم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدمْ ديروكسي ليبوزومال في الحالات التالية:</strong></p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه دوكسوروبيسين هيدروكلوريد، أو الفول السوداني، أو الصويا، أو أيٍّ من المكونات الأخرى لهذا الدواء (مُدرَجة في القسم 6).</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL"><strong>يجب أن تخبر طبيبك عن أيٍّ ممّا يلي:</strong></p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تأخذ أيَّ علاج لأمراض القلب أو الكبد.</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مريضًا بالسكري؛ لأن ديروكسي ليبوزومال يحتوي على السكر، وهو ما يتطلب تعديلًا في علاج السكري الذي تأخذه.</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مريضًا&nbsp; بساركوما كابوزي وقمتَ باستئصال الطحال.</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لاحظتَ تقرحاتٍ أو تغيرًا في اللون أو أيَّ عدم ارتياح في فمك.</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">يجب ألّا يُستخدم ديروكسي ليبوزومال مع الأطفال والمراهقين؛ لأن تأثير الدواء فيهم غير معروف.</p><p dir="RTL"><strong>العقاقير الأخرى وديروكسي ليبوزومال</strong></p><p dir="RTL"><strong>أَخبِرْ طبيبك أو الصيدلي: </strong></p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أو تناولت مؤخرًا أيَّ عقاقير أخرى، بما في ذلك العقاقير التي قد تناولتها بدون وصفة طبية.</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بشأن أيّ أدوية أخرى للسرطان تناولتها أو تتناولها حاليًا، حيث يجب إعطاء عناية خاصة للأدوية التي تُقلِّل عددَ خلايا الدم البيضاء، نظرًا لما قد يسببه ذلك من تخفيضٍ إضافيٍّ في عدد خلايا الدم البيضاء. وإذا لم تكن متأكدًا بشأن الأدوية التي تلقيتها أو بشأن أيّ أمراض أخرى عانيت منها؛ فلتُنَاقِشْ ذلك مع طبيبك.</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL"><strong>استشيري الطبيبَ أو الصيدليَ قبل أخذ أي دواء.</strong></p><p dir="RTL">لأنّ المادة الفعّالة دوكسوروبيسين هيدروكلوريد الموجودة في ديروكسي ليبوزومال قد تُسبِّب تشوهات فى المواليد، فَمِن المهم أنْ تُخبِري طبيبك؛ إذا كُنتِ تعتقدين أنكِ حامل. تجنبي الحملَ في أثناء تناولِك أنتِ أو شريكك دواءَ ديروكسي ليبوزومال وخلال ستة أشهر بعد إيقاف العلاج بدواء ديروكسي ليبوزومال</p><p dir="RTL">يجب أن تتوقف النساء عن الرضاعة الطبيعية قبل البدء في العلاج بدواء ديروكسي ليبوزومال وذلك لأنّ مادة دوكسوروبيسين هيدروكلوريد قد تكون مُضرةً للأطفال الرُّضَّع. يُوصِي خبراءُ الصحة السيداتِ المُصابات بفيروس نقص المناعة البشرية (<strong>HIV</strong>) بألّا يُرضعِنَ أطفالهن رضاعةً طبيعيةً تحت أي ظرفٍ من أجل تجنُّب انتقال الفيروس.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">تجنَّبِ القيادةَ أو استخدامَ أيّ أدوات أو آلات؛ إذا شعرتَ بالإرهاق أو النعاس بسبب تناول دواء ديروكسي ليبوزومال.</p><p dir="RTL"><strong>يحتوي ديروكسي ليبوزومال على زيت الصويا والصوديوم.</strong></p><p dir="RTL">يحتوي ديروكسي ليبوزومال على زيت الصويا. فإذا كنت مصابًا بحساسية الفول السوداني أو الصويا؛ فلا تأخذْ هذا الدواء. يحتوي ديروكسي ليبوزومال على أقل من 1 مللي مول من الصوديوم (23 ملغم) لكل جرعة، وهذا يعني أنه &quot;خالٍ من الصوديوم&quot; بشكلٍ أساسيّ.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">إن تركيبة ديروكسي ليبوزومال تركيبة فريدة. فيجب ألا تُستخدم بشكلٍ تبادُلي مع تركيبات أخرى من مادة دوكسوروبيسين هيدروكلوريد.</p><p dir="RTL"><strong>الجرعة الواجبة من دواء يروكسي ليبوزومال</strong></p><p dir="RTL">إذا كنتِ تُعالَجين من سرطان الثدي أو سرطان المبيض؛ فسيتم أخذ جرعة من ديروكسي ليبوزومال مقدارها 50 ملغم لكل متر مربع من مساحة سطح جسمك (بناءً على طولكِ ووزنكِ). تُكرَّر الجرعة كل 4 أسابيع، وتستمر طالما لم يتحسن المرض وطالما كُنتِ قادرةً على تحمُّل العلاج.</p><p dir="RTL">إذا كنت تعالج من الورم النقوي (النخاعي) المتعدد، وتلقيت بالفعل علاجًا واحدًا سابقًا على الأقل؛ فسيتم أخذ جرعة من ديروكسي ليبوزومال مقدارها 30 ملغم لكل متر مربع من مساحة سطح جسمك (بناءً على طولك ووزنك) عن طريق التنقيط الوريدي لمدة ساعة واحدة في اليوم الرابع من دورة علاج بورتيزوميب &ndash;التي تبلغ مدتها 3 أسابيع&ndash; بعد التنقيط الوريدي لدواء بورتيزوميب مباشرةً. تُكرَّر هذه الجرعة طالما أن استجابتك جيدة وتتحمل العلاج.</p><p dir="RTL">إذا كنت تُعالَج من ساركوما كابوزي؛ فسيتم أخذ جرعة من ديروكسي ليبوزومال مقدارها 20 ملغم لكل متر مربع من مساحة سطح جسمك (بناءً على طولك ووزنك). يتم تكرار الجرعة كل أسبوعين إلى 3 أسابيع ولمدة شهرين إلى 3 أشهر، ثم تُكرَّر الجرعة حسب الحاجة و ذلك للحفاظ على تحسُّن حالتك.</p><p dir="RTL"><strong>كيفية أخذ ديروكسي ليبوزومال</strong></p><p dir="RTL">سيعطيك طبيبك دواء ديروكسي ليبوزومال عن طريق التقطير (الحقن) في الوريد. وسوف يستغرق ذلك مدةً تتراوح من 30 دقيقة إلى ما يزيد عن ساعة (لمدة 90 دقيقة مثلًا) بناءً على الجرعة ودواعي الاستعمال.</p><p dir="RTL"><strong>إذا استخدمت جرعة زائدة من دواء ديروكسي ليبوزومال</strong></p><p dir="RTL">إنّ الجرعة الزائدة بشكلٍ حادّ تجعل الآثار الجانبية أكثر سوءًا مثل تقرحات الفم أو انخفاض أعداد كرات الدم البيضاء والصفائح الدموية. وسوف يتضمن العلاج إعطاءَ مضادات حيوية، ونقل صفائح دموية، واستخدام عوامل تُنشِّط إنتاج خلايا الدم البيضاء وعلاجًا عرَضيًّا لتقرحات الفم.</p><p dir="RTL">إذا كان لديك أي تساؤلات أخرى بشأن استعمال هذا المُنتج؛ فاستشر الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال في كل الأدوية، هذا الدواء يمكن أن يتسبب بأعراض جانبية، بالرغم من أنها قد لا تحدث للجميع.</p><p dir="RTL">وقد تحدث التفاعلات التالية في أثناء الحقن بدواء ديروكسي ليبوزومال:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات تحسُّسيّة حادّة قد تتضمن تورم الوجه، الشفتين، الفم، اللسان أو الحلق؛ صعوبة البلع أو التنفس؛ طفحًا مثيرًا للحكة (شرى)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تهيجَ وضِيق المسالك الهوائية في الرئتين، ممّا يسبب السعال، الأزيز وضيق التنفُّس (الربو)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاحمرار، التعرُّق، قشعريرة برد أو حمى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الصدر أو عدم ارتياح.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم الظهر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدم أو انخفاضه.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرعة نبضات القلب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات (صرع).</p><p dir="RTL">قد يحدث تسرُّب في سائل الحقن من الوريد إلى الأنسجة الموجودة تحت الجلد. إذا شعرت بوخزٍ أو آلام التقطير في أثناء تلقي جرعة ديروكسي ليبوزومال؛ أخبِرْ طبيبك على الفور.</p><p dir="RTL">يجب التواصل مع طبيبك على الفور في حالة ملاحظة أيّ من الآثار الجانبية الخطيرة التالية:</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أُصِبتَ بحمّى، أو شعرت بالإرهاق، أو إذا كانت لديك آثار كدمات أو نزيف (شائعة جدًا).</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار، تورم، تقشُّر أو ألم عند لمس المنطقة المصابة، ويحدث ذلك بشكلٍ أساسي في اليدين أو القدمين (متلازمة &quot;اليد والقدم&quot;).</p><p dir="RTL">وقد تمّ رصد هذه الآثار بشكلٍ شائع جدًا وأحيانًا تكون حادّةً. وقد تتداخل هذه الآثار &ndash;في الحالات الحادة&ndash; مع أنشطة يومية معينة، وقد تدوم لمدة 4 أسابيع أو أكثر قبل حلّها بشكلٍ كامل. قد يرغب الطبيب في تأجيل بدء جرعة العلاج التالي و/أو تقليل الجرعة (انظر استراتيجيات منع متلازمة اليد والقدم وعلاجها أدناه)</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقرحات في الفم، الإسهال الحاد أو القيء أو الغثيان (شائع جدًا).</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى (شائعة)، بما في ذلك عدوى الرئتين (الالتهاب الرئوي) أو التهابات قد تؤثر في الرؤية.</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق التنفس (شائع).</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام حادة في المعدة (شائعة).</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف حاد (شائع).</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات تحسسية حادّة قد تتضمن تورم الوجه، الشفتين، الفم، اللسان أو الحلق؛ صعوبة البلع أو التنفس؛ طفحًا مثيرًا للحكة (شرى) (غير شائعة).</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سكتة قلبية (توقُّف نبض القلب)؛ فشل القلب، حيث لا يضخ القلب دماءً كافيةً لبقية الجسم، وهو ما يسبب ضيق التنفس وقد يؤدي إلى تورم الساقين (غير شائعة).</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جلطة دموية تنتقل إلى الرئتين، مُسببةً آلامًا في الصدر وضيق التنفس (غير شائعة).</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم، سخونة أو ألم عند اللمس في الأنسجة الرخوة في القدم، ويُصاحِبها أحيانًا آلام تُصبِح أكثر سوءًا عند الوقوف أو المشي (نادرة).</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح حاد أو مُهدِّد للحياة تُصاحبه بثور أو تقشٌّر في الجلد، وخاصةً حول الفم، الأنف، العينين والأعضاء التناسلية (متلازمة ستيفنز جونسون) أو في معظم أنحاء الجسم (تقشُّر الأنسجة المتموتة البشروية التسممي) (نادرة).</p><p dir="RTL"><strong>الآثار الجانبية الأخرى</strong></p><p dir="RTL"><strong>قد يحدث ما يلي بين جرعات الحقن:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية شائعة جدًا (قد تُصيب أكثر من شخص واحد من كل 10 أشخاص).</strong></p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض أعداد خلايا الدم البيضاء، وهو ما يمكن أن يزيد من فرص الإصابة بالعدوى.</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وفي حالات نادرة، قد يؤدي انخفاض أعداد خلايا الدم البيضاء إلى الإصابة بعدوى شديدة. وقد تُسبب الأنيميا (انخفاضُ خلايا الدم الحمراء) الشعورَ بالإرهاق، وقد يؤدي انخفاض الصفائح الدموية إلى زيادة خطر النزيف. ونظرًا للتغيُّرات المحتملة في خلايا الدم، فإنك سوف تَخضع لفحص دم دوريّ.</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص الشهية.</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إمساك.</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي، يتضمن احمرار الجلد، الطفح الجلدي التحسسي، الاحمرار أو ظهور الطفح بشكل بارز على الجلد.</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقُط الشعر.</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أوجاع تتضمن آلامًا في العضلات وعضلة الصدر، المفاصل، الذراعين، أو الساقين.</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالإرهاق الشديد.</p><p dir="RTL"><strong>آثار جانبية شائعة (قد تُصيب ما يصل إلى شخصٍ واحد من كل 10 أشخاص):</strong></p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى، بما في ذلك التهاب حادّ على مستوى الجسم (تعفن الدم)، عدوى الرئتين، عدوى فيروس الهربس النطاقي (الحزام الناريّ)، نوع من العدوى البكتيرية (عدوى معقد المتفطرات الطيرية)، التهاب المسالك البولية، الالتهابات الفطرية (بما في ذلك السلاق وسلاق الفم) التهاب بصيلات الشعر، التهاب الحلق أو احتقانه، التهاب الأنف، التهاب الجيوب الأنفية أو التهاب الحلق (نزلة برد).</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض أعداد نوع من خلايا الدم البيضاء (العدلات) يُصاحِبه حمّى.</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان حادّ في الوزن وهزال عضلي، عدم وجود الماء بكفاية في الجسم (جفاف)، انخفاض مستوى البوتاسيوم، الصوديوم أو الكالسيوم في الدم.</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالتشوش، الشعور بالقلق، الاكتئاب، صعوبة النوم.</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تلف الأعصاب الذي قد يسبب الوخز، الخدر، الألم أو فقدان الشعور بالألم، آلام الأعصاب، شعورًا غير طبيعي في الجلد (كالوخز أو التنميل)، نقص الشعور أو الحساسية وبالأخص في الجلد.</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التغير في حاسة التذوق، الصداع، الشعور بالنعاس الشديد مع انخفاض الطاقة، الشعور بالدوار.</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب العين (التهاب الملتحمة).</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرعة نبضات القلب.</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدم أو انخفاضه، الاحمرار.</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق التنفس الذي قد يَنتج عن أنشطة بدنية، نزيف الأنف، السعال.</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب في بطانة المعدة أو المريء، تقرحات في الفم، عسر هضم، صعوبة في البلع، آلام في الفم، جفاف الفم</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في الجلد، تتضمن تقشُّر الجلد أو جفافه، احمرار الجلد، بثورًا أو تقرحاتٍ على الجلد، حكة، بقعًا داكنة على الجلد.</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعرُّق شديد.</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنجات أو آلام عضلية.</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أوجاع تتضمن آلامًا في العضلات، العظام أو الظهر.</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام عند التبول.</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل تحسسي من حقن الدواء، آلام تشبه الأنفلونزا، قشعريرة برد، التهاب في بطانة تجويفات وقنوات الجسم كالأنف، الفم أو القصبة الهوائية، الشعور بالضعف، الشعور بالتعب العام، تورم يسببه تراكم السائل في الجسم، تورم اليدين، الكاحلين أو القدمين.</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوزن</p><p dir="RTL"><strong>عند استخدام دواء ديروكسي ليبوزومال وحده؛ تَقِلّ احتمالية حدوث بعض هذه الآثار، وبعضها لا يحدث إطلاقًا.</strong></p><p dir="RTL"><strong>آثار جانبية غير شائعة (قد تصيب ما يصل إلى شخص واحد من كل 100 شخص):</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى فيروس الهربس البسيطة (قرحة البرد أو الهربس التناسلي)، العدوى الفطرية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض أعداد جميع أنواع خلايا الدم، وزيادة أعداد &quot;الصفائح الدموية&quot; (الخلايا التي تساعد في تجلط الدم).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل تحسسي.</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستوى البوتاسيوم في الدم، وانخفاض مستوى الماغنسيوم في الدم.</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تلف الأعصاب الذي يؤثر في أكثر من منطقة في الجسم.</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات (صرع)، إغماء.</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إحساس مؤلم أو غير مريح، وخاصةً عند اللمس، شعور بالنعاس.</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضبابية في الرؤية، دموع بالعينين.</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بسرعة نبضات القلب أو عدم تعادُلها (الخفقان)، اعتلال عضلة القلب، فشل القلب.</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تلف الأنسجة (نخر) في مكان الحقن، التهاب الأوردة التي تسبب التورم والألم، الشعور بالدوار عند الاعتدال أو الوقوف.</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالضيق في الصدر.</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خروج غازات، التهاب اللثة.</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في الجلد أو طفح، بما في ذلك تقشُّر أو ترقُّق الجلد، طفح الجلد التحسسي، تقرحات أو بثور على الجلد، تغير لون الجلد، تغير في اللون الطبيعي (صبغة) الجلد، نقاط صغيرة حمراء أو أرجوانية بسبب النزيف تحت الجلد، مشاكل في الأظافر، حَبّ الشباب.</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف العضلات.</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام في الثديين.</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تهيج أو آلام في مكان الحقن.</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الوجه، ارتفاع درجة حرارة الجسم.</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عودة أعراضٍ (كالالتهاب، الاحمرار أو الألم) في مناطق الجسم التي تَلقَّتْ علاجًا إشعاعيًّا في السابق أو التي تعرَّضت للتلف من قَبلُ بسبب حقن العلاج الكيميائي في الوريد.</p><p dir="RTL"><strong>آثار جانبية نادرة (قد تصيب ما يصل إلى شخص واحد من كل 1000 شخص):</strong></p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الالتهابات التي تَحدُث لدى ذوي الجهاز المناعي الضعيف.</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض أعداد خلايا الدم الذي ينتج من قبل نخاع العظم.</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الشبكية الذي قد يُسبِّب تغيرات في الرؤية أو عمىً.</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إيقاع غير طبيعي في القلب، تتبُّع غير طبيعي في القلب على مُخطَّط كهربيةِ القلب (ECG) وقد يكون مصحوبًا ببطء في نبضات القلب، مشاكل في القلب تؤثر في نبض القلب وإيقاعه، زُرقة لون الجلد ومادة مخاطية بسبب انخفاض الأكسجين في الدم.</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; توسع الأوعية الدموية.</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بضيق وانغلاق الحلق.</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم وتقرح اللسان، تقرحات على الشفاه.</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي تُصاحبه بثور متقيحة.</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب في المهبل، احمرار الصفن.</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في بطانة تجويفات وقنوات الجسم، كالأنف، الفم أو القصبة الهوائية.</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نتائج غير طبيعية في فحص الدم للكبد، وزيادة مستوى &quot;الكرياتينين&quot; في الدم</p><p dir="RTL"><strong>غير معروفة (لا يمكن تقدير معدل التكرار من البيانات المتاحة)</strong></p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الدم الذي يتطور بسرعة ويؤثر في خلايا الدم (الابيضاض النقوي الحاد)، مرض النخاع العظمي الذي يؤثر في خلايا الدم (متلازمة خلل التنسج النخاعي)، سرطان الفم أو الشفاه.</p><p dir="RTL"><strong><u>استراتيجيات لمنع متلازمة اليد والقدم و علاجها التي تتضمن:</u></strong></p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقع اليدين و/أو القدمين في حوض ماء بارد عند الإمكان (على سبيل المثال، في أثناء مشاهدة التلفاز، أو القراءة، أو الاستماع إلى الراديو).</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إبقاء اليدين أو القدمين عاريتين (بدون قفازات أو جوارب أو ما إلى ذلك).</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البقاء في الأماكن الباردة.</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخذ حمام بارد في أثناء الطقس الحار.</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تجنب التمارين الشاقة التي قد تسبب كدمات للقدم (مثل الهرولة).</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تجنب تعريض الجلد للطقس شديد الحرارة (مثل: الجاكوزي والساونا).</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تجنب الأحذية الضيقة، أو انتعال أحذية الكعب العالي.</p><p dir="RTL">بردوكسين (فيتامين ب 6):</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يتوفر فيتامين ب 6 بدون وصفة طبية.</p><p dir="RTL">&shy;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناوُل مقدارٍ من 50 إلى 150 ملغم يوميًا مع بداية أُولَى علامات الاحمرار أو الوخز.</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إن كان لديك أعراض جانبية أو لاحظت أعراض جانبية غير مذكورة في هذه النشرة، فضلًا ابلغ &lt;الطبيب&gt; &lt;أو&gt; &lt;مقدم الرعاية الصحية&gt; &lt;أو&gt; &lt;الصيدلي&gt;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظْ هذا الدواء بعيدًا عن مرأى ومُتناوَل الأطفال.</p><p dir="RTL">يُخزَّن في الثلاجة بدرجة حرارة (من 2 إلى 8 درجات مئوية). لا تُجمِّدْ هذا الدواء.</p><p dir="RTL"><strong>بعد التخفيف:</strong></p><p dir="RTL">يَظهر استقرار كيميائي ومادّيّ في أثناء الاستخدام لمدة 24 ساعة في درجة حرارة من 2 إلى 8 درجات مئوية.</p><p dir="RTL">من وجهةِ نظرٍ ميكروبيولوجية، يجب استخدام المُنتَج بشكلٍ فوريّ. وإذا لم يتم استخدامه فورًا؛ فإن أوقات التخزين في أثناء الاستخدام وظروف التخزين قبل الاستخدام تكون ضِمنَ مسؤولية المُستخدِم، ويجب ألّا تَطوُل المدة عن 24 ساعة في درجة حرارة من 2 إلى 8 درجات مئوية، ويجب التخلص من القنينات التي تمّ استخدام جزء منها.</p><p dir="RTL">لا تستخدمْ هذا الدواء بعد تاريخ انتهاء الصلاحية المُدوَّن على الملصق والعبوة الخارجية.</p><p dir="RTL">لا تستخدمْ هذا الدواء؛ إذا لاحظتَ ظهور أدلةٍ على الترسيب أو أيّ مادة جزيئية دقيقة.</p><p dir="RTL">تَجنَّب التخلص من أيّ أدوية في مياه الصرف أو مع النفايات المنزلية. اِسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تَعُدْ تستخدمها. اتبعْ هذه الإجراءات للحفاظ على سلامة البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قنينة زجاجية أنبوبية شفافة من النوع الأول حجم 10 مل/20مم مُغلقة بِسدادة رمادية اللون من مطاط البوتيل من النوع الأول مكتوب عليها 20مم ومختومة بختم مقلوب مكتوب عليه 20مم.</p><p dir="RTL">يتم توفيرها في عبوة واحدة.</p><p dir="RTL">قنينة زجاجية أنبوبية شفافة من النوع الأول موافقة لدستور الأدوية الأمريكي (USP) حجم 30 مل/20مم مُغلقة بِسدادة أنبوب رمادية اللون من مطاط البوتيل من النوع الأول مكتوب عليها 20مم، ومختومة بختم مقلوب مكتوب عليه 20مم.</p><p dir="RTL">يتم توفيرها في عبوة واحدة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قنينة زجاجية أنبوبية شفافة من النوع الأول حجم 10 مل/20مم مُغلقة بِسدادة رمادية اللون من مطاط البوتيل من النوع الأول مكتوب عليها 20مم ومختومة بختم مقلوب مكتوب عليه 20مم.</p><p dir="RTL">يتم توفيرها في عبوة واحدة.</p><p dir="RTL">قنينة زجاجية أنبوبية شفافة من النوع الأول موافقة لدستور الأدوية الأمريكي (USP) حجم 30 مل/20مم مُغلقة بِسدادة أنبوب رمادية اللون من مطاط البوتيل من النوع الأول مكتوب عليها 20مم، ومختومة بختم مقلوب مكتوب عليه 20مم.</p><p dir="RTL">يتم توفيرها في عبوة واحدة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>صاحب رخصة التسويق:</strong></p><p dir="RTL">شركة سدير للأدوية (SPC)</p><p dir="RTL">طريق الملك فهد، مبنى 8006 - الطابق الرابع، الرياض، المملكة العربية السعودية</p><p dir="RTL">هاتف: &lrm;+966-11-920001432</p><p dir="RTL">فاكس: +966-11-4668195</p><p dir="RTL">البريد الإلكتروني: info@sudairpharma.com</p><p dir="RTL">المُراسَلة بالبريد: صندوق بريد 12363، الرياض، المملكة العربية السعودية</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشركة المُصنِّعة:</strong></p><p dir="RTL">شركة ناتكو فارما المحدودة</p><p dir="RTL">Pharma Division, Unit-V Kothur,</p><p dir="RTL">Rangareddy District, Telangana - 509 228,</p><p dir="RTL">الهند</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            03/2021
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Deroxi Liposomal Injection 20mg/10ml (2mg/ml)  
Deroxi Liposomal Injection 50mg/25ml (2mg/ml)  
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One ml contains 2 mg doxorubicin hydrochloride in a pegylated liposomal formulation.
Doxorubicin Liposomal, a liposome formulation, is doxorubicin hydrochloride encapsulated in liposomes with surface-bound methoxypolyethylene glycol (MPEG). This process is known as pegylation and protects liposomes from detection by the mononuclear phagocyte system (MPS), which increases blood circulation time.
Excipients with known effect Contains fully hydrogenated soy phosphatidylcholine (from soyabean) - see section 4.3 Contains less than 1 mmol sodium (23 mg) per dose, and is essentially 'sodium free'. 
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Concentrate for solution for infusion in a pegylated liposomal formulation.
The suspension is translucent and red.
pH: Between 6.0 and 7.0
Osmolality: Between 310 and 390 mOsm/Kg of water
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Doxorubicin Liposomal is indicated:</p><p>- As monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk.</p><p>- For treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen.</p><p>- In combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant.</p><p>- For treatment of AIDS-related Kaposi&#39;s sarcoma (KS) in patients with low CD4 counts (&lt; 200 CD4 lymphocytes/mm<sup>3</sup>) and extensive mucocutaneous or visceral disease.</p><p>Doxorubicin Liposomal can be used as first-line systemic chemotherapy, or as second line chemotherapy in AIDS-KS patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Doxorubicin Liposomal should only be administered under the supervision of a qualified oncologist specialised in the administration of cytotoxic agents.</p><p>Doxorubicin Liposomal exhibits unique pharmacokinetic properties and must not be used interchangeably with other formulations of doxorubicin hydrochloride.</p><p><u>Posology</u></p><p><em><u>Breast cancer/Ovarian cancer</u></em></p><p>Doxorubicin Liposomal is administered intravenously at a dose of 50 mg/m<sup>2 </sup>once every 4 weeks for as long as the disease does not progress and the patient continues to tolerate treatment.</p><p><em><u>Multiple myeloma</u></em></p><p>Doxorubicin Liposomal is administered at 30 mg/m&sup2; on day 4 of the bortezomib 3 week regimen as a 1 hour infusion administered immediately after the bortezomib infusion. The bortezomib regimen consists of 1.3 mg/m&sup2; on days 1, 4, 8, and 11 every 3 weeks. The dose should be repeated as long as patients respond satisfactorily and tolerate treatment. Day 4 dosing of both medicinal products may be delayed up to 48 hours as medically necessary. Doses of bortezomib should be at least 72 hours apart.</p><p><em><u>AIDS-related KS</u></em></p><p>Doxorubicin Liposomal is administered intravenously at 20 mg/m<sup>2</sup>&nbsp;every two-to-three weeks. Avoid intervals shorter than 10 days as medicinal product accumulation and increased toxicity cannot be ruled out. Treatment of patients for two-to-three months is recommended to achieve a therapeutic response. Continue treatment as needed to maintain a therapeutic response.</p><p><em><u>For all patients</u></em></p><p>If the patient experiences early symptoms or signs of infusion reaction, immediately discontinue the infusion, give appropriate premedications (antihistamine and/or short acting corticosteroid) and restart at a slower rate.</p><p><em><u>Guidelines for </u></em><em><u>Doxorubicin </u></em><em><u>dose modification</u></em></p><p>To manage adverse events such as palmar-plantar erythrodysesthesia (PPE), stomatitis or haematological toxicity, the dose may be reduced or delayed. Guidelines for Doxorubicin dose modification secondary to these adverse effects are provided in the tables below. The toxicity grading in these tables is based on the National Cancer Institute Common Toxicity Criteria (NCI-CTC).</p><p>The tables for PPE (Table 1) and stomatitis (Table 2) provide the schedule followed for dose modification in clinical trials in the treatment of breast or ovarian cancer (modification of the recommended 4 week treatment cycle): if these toxicities occur in patients with AIDS-related KS, the recommended 2 to 3 week treatment cycle can be modified in a similar manner.</p><p>The table for haematological toxicity (Table 3) provides the schedule followed for dose modification in clinical trials in the treatment of patients with breast or ovarian cancer only. Dose modification in patients with AIDS-KS is provided following Table 4.</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>Table 1. Palmar&ndash;Plantar erythrodysesthesia</strong></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td colspan="3" style="vertical-align:top"><p><strong>Week after prior Doxorubicin dose</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Toxicity grade at current assessment</strong></p></td><td style="vertical-align:top"><p><strong>Week 4</strong></p></td><td style="vertical-align:top"><p><strong>Week 5</strong></p></td><td style="vertical-align:top"><p><strong>Week 6</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Grade 1</strong></p><p>(mild erythema, swelling, or desquamation not interfering with daily activities)</p></td><td style="vertical-align:top"><p><strong>Redose unless</strong></p><p>patient has experienced a previous grade 3 or 4 skin toxicity, in which case wait an additional week</p></td><td style="vertical-align:top"><p><strong>Redose unless</strong></p><p>patient has experienced a previous grade 3 or 4 skin toxicity, in which case wait an additional week</p></td><td style="vertical-align:top"><p><strong>Decrease dose by 25%; return to 4 week interval</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Grade 2</strong></p><p>(erythema, desquamation, or swelling interfering with, but not precluding normal physical activities; small blisters or ulcerations less than 2 cm in diameter)</p></td><td style="vertical-align:top"><p><strong>Wait an additional week</strong></p></td><td style="vertical-align:top"><p><strong>Wait an additional week</strong></p></td><td style="vertical-align:top"><p><strong>Decrease dose by 25%; return to 4 week interval</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Grade 3</strong></p><p>(blistering, ulceration, or swelling interfering with walking or normal daily activities; cannot wear regular clothing)</p></td><td style="vertical-align:top"><p><strong>Wait an additional week</strong></p></td><td style="vertical-align:top"><p><strong>Wait an additional week</strong></p></td><td style="vertical-align:top"><p><strong>Withdraw patient</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Grade 4</strong></p><p>(diffuse or local process causing infectious complications, or a bedridden state or hospitalisation)</p></td><td style="vertical-align:top"><p><strong>Wait an additional week</strong></p></td><td style="vertical-align:top"><p><strong>Wait an additional week</strong></p></td><td style="vertical-align:top"><p><strong>Withdraw patient</strong></p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>Table 2. Stomatitis</strong></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td colspan="3" style="vertical-align:top"><p><strong>Week after prior doxorubicin dose</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Toxicity grade at current assessment</strong></p></td><td style="vertical-align:top"><p><strong>Week 4</strong></p></td><td style="vertical-align:top"><p><strong>Week 5</strong></p></td><td style="vertical-align:top"><p><strong>Week 6</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Grade 1</strong></p><p>(painless ulcers, erythema, or mild soreness)</p></td><td style="vertical-align:top"><p><strong>Redose unless</strong></p><p>patient has experienced a previous grade 3 or 4 stomatitis in which case wait an additional week</p></td><td style="vertical-align:top"><p><strong>Redose unless</strong></p><p>patient has experienced a previous grade 3 or 4 stomatitis in which case wait an additional week</p></td><td style="vertical-align:top"><p><strong>Decrease dose by 25%; return to 4 week interval&nbsp;</strong>or withdraw patient per physician&#39;s assessment</p></td></tr><tr><td style="vertical-align:top"><p><strong>Grade 2</strong></p><p>(painful erythema, oedema, or ulcers, but can eat)</p></td><td style="vertical-align:top"><p><strong>Wait an additional week</strong></p></td><td style="vertical-align:top"><p><strong>Wait an additional week</strong></p></td><td style="vertical-align:top"><p><strong>Decrease dose by 25%; return to 4 week interval&nbsp;</strong>or withdraw patient per physician&#39;s assessment</p></td></tr><tr><td style="vertical-align:top"><p><strong>Grade 3</strong></p><p>(painful erythema, edema, or ulcers, but cannot eat)</p></td><td style="vertical-align:top"><p><strong>Wait an additional week</strong></p></td><td style="vertical-align:top"><p><strong>Wait an additional week</strong></p></td><td style="vertical-align:top"><p><strong>Withdraw patient</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Grade 4</strong></p><p>(requires parenteral or enteral support)</p></td><td style="vertical-align:top"><p><strong>Wait an additional week</strong></p></td><td style="vertical-align:top"><p><strong>Wait an additional week</strong></p></td><td style="vertical-align:top"><p><strong>Withdraw patient</strong></p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>Table 3. Haematological toxicity (ANC or platelets) &ndash; Management of patients with breast or ovarian cancer</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>GRADE</strong></p></td><td style="vertical-align:top"><p><strong>ANC</strong></p></td><td style="vertical-align:top"><p><strong>PLATELETS</strong></p></td><td style="vertical-align:top"><p><strong>MODIFICATION</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Grade 1</strong></p></td><td style="vertical-align:top"><p>1,500 &ndash; 1,900</p></td><td style="vertical-align:top"><p>75,000 &ndash; 150,000</p></td><td style="vertical-align:top"><p>Resume treatment with no dose reduction.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Grade 2</strong></p></td><td style="vertical-align:top"><p>1,000 &ndash; &lt; 1,500</p></td><td style="vertical-align:top"><p>50,000 &ndash; &lt; 75,000</p></td><td style="vertical-align:top"><p>Wait until ANC &ge; 1,500 and platelets &ge; 75,000; redose with no dose reduction.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Grade 3</strong></p></td><td style="vertical-align:top"><p>500 &ndash; &lt; 1,000</p></td><td style="vertical-align:top"><p>25,000 &ndash; &lt; 50,000</p></td><td style="vertical-align:top"><p>Wait until ANC &ge; 1,500 and platelets &ge; 75,000; redose with no dose reduction.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Grade 4</strong></p></td><td style="vertical-align:top"><p>&lt; 500</p></td><td style="vertical-align:top"><p>&lt; 25,000</p></td><td style="vertical-align:top"><p>Wait until ANC &ge; 1,500 and platelets &ge; 75,000; decrease dose by 25% or continue full dose with growth factor support.</p></td></tr></tbody></table><p>For multiple myeloma patients treated with Doxorubicin liposomal in combination with bortezomib who experience PPE or stomatitis, the Doxorubicin liposomal dose should be modified as described in Table 1 and 2 above respectively. Table 4, below provides the schedule followed for other dose modifications in the clinical trial in the treatment of patients with multiple myeloma receiving Doxorubicin liposomal and bortezomib combination therapy. For more detailed information on bortezomib dosing and dosage adjustments, see the SmPC for bortezomib.</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Table 4. Dosage adjustments for </strong><strong>Doxorubicin </strong><strong>liposomal + bortezomib combination therapy - patients with multiple myeloma</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Patient status</strong></p></td><td style="vertical-align:top"><p><strong>Doxorubicin </strong><strong>liposomal</strong></p></td><td style="vertical-align:top"><p><strong>Bortezomib</strong></p></td></tr><tr><td style="vertical-align:top"><p>Fever &ge; 38<sup>○</sup>C and ANC &lt; 1,000/mm<sup>3</sup></p></td><td style="vertical-align:top"><p>Do not dose this cycle if before day 4; if after day 4, reduce next dose by 25%.</p></td><td style="vertical-align:top"><p>Reduce next dose by 25%.</p></td></tr><tr><td style="vertical-align:top"><p>On any day of medicine administration after day 1 of each cycle:</p><p>Platelet count &lt; 25,000/mm<sup>3</sup></p><p>Haemoglobin &lt; 8 g/dl</p><p>ANC &lt; 500/mm<sup>3</sup></p></td><td style="vertical-align:top"><p>Do not dose this cycle if before day 4; if after day 4 reduce next dose by 25% in the following cycles if bortezomib is reduced for haematologic toxicity.*</p></td><td style="vertical-align:top"><p>Do not dose; if 2 or more doses are not given in a cycle, reduce dose by 25% in following cycles.</p></td></tr><tr><td style="vertical-align:top"><p>Grade 3 or 4 non-haematologic medicine related toxicity</p></td><td style="vertical-align:top"><p>Do not dose until recovered to grade &lt; 2 and reduce dose by 25% for all subsequent doses.</p></td><td style="vertical-align:top"><p>Do not dose until recovered to grade &lt; 2 and reduce dose by 25% for all subsequent doses.</p></td></tr><tr><td style="vertical-align:top"><p>Neuropathic pain or peripheral neuropathy</p></td><td style="vertical-align:top"><p>No dosage adjustments.</p></td><td style="vertical-align:top"><p>See the SmPC for bortezomib.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>* for more information on bortezomib dosing and dosage adjustment, see the SmPC for bortezomib</p></td></tr></tbody></table><p>For AIDS-KS patients treated with Doxorubicin liposomal, haematological toxicity may require dose reduction or suspension or delay of therapy. Temporarily suspend Doxorubicin liposomal treatment in patients when the ANC count is &lt; 1,000/mm<sup>3</sup>&nbsp;and/or the platelet count is &lt; 50,000/mm<sup>3</sup>. G-CSF (or GM-CSF) may be given as concomitant therapy to support the blood count when the ANC count is &lt; 1,000/mm<sup>3</sup>&nbsp;in subsequent cycles.</p><p><em><u>Hepatic Impairment</u></em></p><p>Doxorubicin liposomal pharmacokinetics determined in a small number of patients with elevated total bilirubin levels do not differ from patients with normal total bilirubin; however, until further experience is gained, the Doxorubicin liposomal dosage in patients with impaired hepatic function should be reduced based on the experience from the breast and ovarian clinical trial programs as follows: at initiation of therapy, if the bilirubin is between 1.2-3.0 mg/dl, the first dose is reduced by 25%. If the bilirubin is &gt; 3.0 mg/dl, the first dose is reduced by 50%. If the patient tolerates the first dose without an increase in serum bilirubin or liver enzymes, the dose for cycle 2 can be increased to the next dose level, i.e., if reduced by 25% for the first dose, increase to full dose for cycle 2; if reduced by 50% for the first dose, increase to 75% of full dose for cycle 2. The dosage can be increased to full dose for subsequent cycles if tolerated. Doxorubicin liposomal can be administered to patients with liver metastases with concurrent elevation of bilirubin and liver enzymes up to 4 x the upper limit of the normal range. Prior to Doxorubicin liposomal administration, evaluate hepatic function using conventional clinical laboratory tests such as ALT/AST, alkaline phosphatase, and bilirubin.</p><p><em><u>Renal Impairment</u></em></p><p>As doxorubicin liposomal is metabolised by the liver and excreted in the bile, dose modification should not be required. Population pharmacokinetic data (in the range of creatinine clearance tested of 30-156 ml/min) demonstrate that Doxorubicin liposomal clearance is not influenced by renal function. No pharmacokinetic data are available in patients with creatinine clearance of less than 30 ml/min.</p><p><em><u>AIDS-related KS patients with splenectomy</u></em></p><p>As there is no experience with Doxorubicin liposomal in patients who have had splenectomy, treatment with Doxorubicin liposomal is not recommended.</p><p><em><u>Paediatric population</u></em></p><p>The experience in children is limited. Doxorubicin liposomal is not recommended in patients below 18 years of age.</p><p><em><u>Elderly</u></em></p><p>Population based analysis demonstrates that age across the range tested (21&ndash;75 years) does not significantly alter the pharmacokinetics of Doxorubicin liposomal.</p><p><u>Method of administration</u></p><p>Doxorubicin liposomal is administered as an intravenous infusion. For further instructions on preparation and special precautions for handling (see section 6.6).</p><p>Do not administer Doxorubicin liposomal as a bolus injection or undiluted solution. It is recommended that the Doxorubicin liposomal infusion line be connected through the side port of an intravenous infusion of 5% (50 mg/ml) glucose to achieve further dilution and minimise the risk of thrombosis and extravasation. The infusion may be given through a peripheral vein. Do not use with in-line filters. Doxorubicin Liposomal must not be given by the intramuscular or subcutaneous route (see section 6.6).</p><p>For doses &lt; 90 mg: dilute Doxorubicin liposomal in 250 ml 5% (50 mg/ml) glucose solution for infusion.</p><p>For doses &ge; 90 mg: dilute Doxorubicin liposomal in 500 ml 5% (50 mg/ml) glucose solution for infusion.</p><p><em><u>Breast cancer/Ovarian cancer/Multiple myeloma</u></em></p><p>To minimise the risk of infusion reactions, the initial dose is administered at a rate no greater than 1 mg/minute. If no infusion reaction is observed, subsequent Doxorubicin liposomal infusions may be administered over a 60-minute period.</p><p>In those patients who experience an infusion reaction, the method of infusion should be modified as follows:</p><p>5% of the total dose should be infused slowly over the first 15 minutes. If tolerated without reaction, the infusion rate may then be doubled for the next 15 minutes. If tolerated, the infusion may then be completed over the next hour for a total infusion time of 90 minutes.</p><p><em><u>AIDS-related KS</u></em></p><p>The dose of Doxorubicin liposomal is diluted in 250 ml 5% (50 mg/ml) glucose solution for infusion and administered by intravenous infusion over 30 minutes.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Hypersensitivity to the active substance, peanut or soya, or to any of the excipients listed in section 6.1.
•	Doxorubicin liposomal must not be used to treat AIDS-KS that may be treated effectively with local therapy or systemic alfa-interferon.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Given the difference in pharmacokinetic profiles and dosing schedules, Doxorubicin liposomal should not be used interchangeably with other formulations of doxorubicin hydrochloride.</p><p><u>Cardiac toxicity</u></p><p>It is recommended that all patients receiving Doxorubicin liposomal routinely undergo frequent ECG monitoring. Transient ECG changes such as T-wave flattening, S-T segment depression and benign arrhythmias are not considered mandatory indications for the suspension of Doxorubicin liposomal therapy. However, reduction of the QRS complex is considered more indicative of cardiac toxicity. If this change occurs, the most definitive test for anthracycline myocardial injury, i.e., endomyocardial biopsy, must be considered.</p><p>More specific methods for the evaluation and monitoring of cardiac functions as compared to ECG are a measurement of left ventricular ejection fraction by echocardiography or preferably by Multigated Angiography (MUGA). These methods must be applied routinely before the initiation of Doxorubicin liposomal therapy and repeated periodically during treatment. The evaluation of left ventricular function is considered to be mandatory before each additional administration of Doxorubicin liposomal that exceeds a lifetime cumulative anthracycline dose of 450 mg/m<sup>2</sup>.</p><p>The evaluation tests and methods mentioned above concerning the monitoring of cardiac performance during anthracycline therapy are to be employed in the following order: ECG monitoring, measurement of left ventricular ejection fraction, endomyocardial biopsy. If a test result indicates possible cardiac injury associated with Doxorubicin therapy, the benefit of continued therapy must be carefully weighed against the risk of myocardial injury.</p><p>In patients with cardiac disease requiring treatment, administer Doxorubicin only when the benefit outweighs the risk to the patient.</p><p>Exercise caution in patients with impaired cardiac function who receive Doxorubicin Liposomal.</p><p>Whenever cardiomyopathy is suspected, i.e., the left ventricular ejection fraction has substantially decreased relative to pre-treatment values and/or left ventricular ejection fraction is lower than a prognostically relevant value (e.g., &lt; 45%), endomyocardial biopsy may be considered and the benefit of continued therapy must be carefully evaluated against the risk of developing irreversible cardiac damage.</p><p>Congestive heart failure due to cardiomyopathy may occur suddenly, without prior ECG changes and may also be encountered several weeks after discontinuation of therapy.</p><p>Caution must be observed in patients who have received other anthracyclines. The total dose of doxorubicin hydrochloride must also take into account any previous (or concomitant) therapy with cardiotoxic compounds such as other anthracyclines/anthraquinones or e.g., 5-fluorouracil. Cardiac toxicity also may occur at cumulative anthracycline doses lower than 450 mg/m<sup>2</sup>&nbsp;in patients with prior mediastinal irradiation or in those receiving concurrent cyclophosphamide therapy.</p><p>The cardiac safety profile for the dosing schedule recommended for both breast and ovarian cancer (50 mg/m<sup>2</sup>) is similar to the 20 mg/m<sup>2</sup>&nbsp;profile in patients with AIDS-KS (see section 4.8).</p><p><u>Myelosuppression</u></p><p>Many patients treated with Doxorubicin liposomal have baseline myelosuppression due to such factors as their pre-existing HIV disease or numerous concomitant or previous medications, or tumours involving bone marrow. In the pivotal trial in patients with ovarian cancer treated at a dose of 50 mg/m<sup>2</sup>, myelosuppression was generally mild to moderate, reversible, and was not associated with episodes of neutropaenic infection or sepsis. Moreover, in a controlled clinical trial of Doxorubicin liposomal vs. topotecan, the incidence of treatment related sepsis was substantially less in the Doxorubicin liposomal-treated ovarian cancer patients as compared to the topotecan treatment group. A similar low incidence of myelosuppression was seen in patients with metastatic breast cancer receiving Doxorubicin liposomal in a first-line clinical trial. In contrast to the experience in patients with breast cancer or ovarian cancer, myelosuppression appears to be the dose-limiting adverse event in patients with AIDS-KS. Because of the potential for bone marrow suppression, periodic blood counts must be performed frequently during the course of Doxorubicin liposomal therapy, and at a minimum, prior to each dose of Doxorubicin liposomal.</p><p>Persistent severe myelosuppression, may result in superinfection or haemorrhage.</p><p>In controlled clinical studies in patients with AIDS-KS against a bleomycin/vincristine regimen, opportunistic infections were apparently more frequent during treatment with Doxorubicin liposomal. Patients and doctors must be aware of this higher incidence and take action as appropriate.</p><p><u>Secondary haematological malignancies</u></p><p>As with other DNA-damaging antineoplastic agents, secondary acute myeloid leukemias and myelodysplasias have been reported in patients having received combined treatment with doxorubicin liposomal. Therefore, any patient treated with doxorubicin should be kept under haematological supervision.</p><p><u>Secondary oral neoplasms</u></p><p>Very rare cases of secondary oral cancer have been reported in patients with long-term (more than one year) exposure to Doxorubicin liposomal or those receiving a cumulative Doxorubicin liposomal dose greater than 720 mg/m<sup>2</sup>. Cases of secondary oral cancer were diagnosed both, during treatment with Doxorubicin liposomal, and up to 6 years after the last dose. Patients should be examined at regular intervals for the presence of oral ulceration or any oral discomfort that may be indicative of secondary oral cancer.</p><p><u>Infusion-associated reactions</u></p><p>Serious and sometimes life-threatening infusion reactions, which are characterised by allergic-like or anaphylactoid-like reactions, with symptoms including asthma, flushing, urticarial rash, chest pain, fever, hypertension, tachycardia, pruritus, sweating, shortness of breath, facial oedema, chills, back pain, tightness in the chest and throat and/or hypotension may occur within minutes of starting the infusion of Doxorubicin liposomal. Very rarely, convulsions also have been observed in relation to infusion reactions. Temporarily stopping the infusion usually resolves these symptoms without further therapy. However, medications to treat these symptoms (e.g., antihistamines, corticosteroids, adrenaline, and anticonvulsants), as well as emergency equipment should be available for immediate use. In most patients treatment can be resumed after all symptoms have resolved, without recurrence. Infusion reactions rarely recur after the first treatment cycle. To minimise the risk of infusion reactions, the initial dose should be administered at a rate no greater than 1 mg/minute (see section 4.2).</p><p><u>Palmar plantar erythrodysaesthesia syndrome (PPE)</u></p><p>PPE is characterised by painful, macular reddening skin eruptions. In patients experiencing this event, it is generally seen after two or three cycles of treatment. Improvement usually occurs in 1-2 weeks, and in some cases, may take up to 4 weeks or longer for complete resolution. Pyridoxine at a dose of 50-150 mg per day and corticosteroids have been used for the prophylaxis and treatment of PPE, however, these therapies have not been evaluated in phase III trials. Other strategies to prevent and treat PPE include keeping hands and feet cool, by exposing them to cool water (soaks, baths, or swimming), avoiding excessive heat/hot water and keeping them unrestricted (no socks, gloves, or shoes that are tight fitting). PPE appears to be primarily related to the dose schedule and can be reduced by extending the dose interval 1-2 weeks (see section 4.2). However, this reaction can be severe and debilitating in some patients and may require discontinuation of treatment (see section 4.8).</p><p><u>Extravasation</u></p><p>Although local necrosis following extravasation has been reported very rarely, doxorubicin liposomal is considered to be an irritant. Animal studies indicate that administration of doxorubicin hydrochloride as a liposomal formulation reduces the potential for extravasation injury. If any signs or symptoms of extravasation occur (e.g., stinging, erythema) terminate the infusion immediately and restart in another vein. The application of ice over the site of extravasation for approximately 30 minutes may be helpful in alleviating the local reaction. Doxorubicin Pegylated liposomal must not be given by the intramuscular or subcutaneous route.</p><p><u>Diabetic patients</u></p><p>Please note that each vial of Doxorubicin liposomal contains sucrose and the dose is administered in 5% (50 mg/ml) glucose solution for infusion.</p><p><u>Excipients</u>[MA1]&nbsp;</p><p>This medicine contains less than 1 mmol sodium (23 mg) per dose and is essentially &#39;sodium-free&#39;.</p><p>For common adverse events which required dose modification or discontinuation see section 4.8.</p><p>&nbsp;[MA1]These excipients are in brand</p><p><strong>note: if we have same excipients please add. If not, then add our excipients if there any Special warnings.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No formal medicinal product interaction studies have been performed with Doxorubicin, although phase II combination trials with conventional chemotherapy agents have been conducted in patients with gynaecological malignancies. Exercise caution in the concomitant use of medicinal products known to interact with standard doxorubicin hydrochloride. Doxorubicin, like other doxorubicin hydrochloride preparations, may potentiate the toxicity of other anti-cancer therapies. During clinical trials in patients with solid tumours (including breast and ovarian cancer) who have received concomitant cyclophosphamide or taxanes, no new additive toxicities were noted. In patients with AIDS, exacerbation of cyclophosphamide-induced haemorrhagic cystitis and enhancement of the hepatotoxicity of 6-mercaptopurine have been reported with standard doxorubicin hydrochloride. Caution must be exercised when giving any other cytotoxic agents, especially myelotoxic agents, at the same time.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>Doxorubicin hydrochloride is suspected to cause serious birth defects when administered during pregnancy. Therefore, Doxorubicin hydrochloride should not be used during pregnancy unless clearly necessary.</p><p><u>Women of child-bearing potential</u></p><p>Women of child-bearing potential must be advised to avoid pregnancy while they or their male partner are receiving Doxorubicin hydrochloride and in the six months following discontinuation of Doxorubicin hydrochloride therapy.</p><p><u>Breast-feeding</u></p><p>It is not known whether Doxorubicin hydrochloride is excreted in human milk. Because many medicinal products, including anthracyclines, are excreted in human milk, and because of the potential for serious adverse reactions in nursing infants, therefore mothers must discontinue nursing prior to beginning Doxorubicin hydrochloride treatment. Health experts recommend that HIV infected women do not breast-feed their infants under any circumstances in order to avoid transmission of HIV.</p><p><u>Fertility</u></p><p>The effect of doxorubicin hydrochloride on human fertility has not been evaluated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Doxorubicin pegylated liposomal has no or negligible influence on the ability to drive and use machines. However, in clinical studies to date, dizziness and somnolence were associated infrequently (&lt; 5%) with the administration of doxorubicin pegylated liposomal. Patients who suffer from these effects must avoid driving and operating machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>The most frequent adverse reactions (&ge; 20%) were neutropaenia, nausea, leukopaenia, anaemia, and fatigue.</p><p>Severe adverse reactions (Grade 3/4 adverse reactions occurring in &ge; 2% of patients) were neutropaenia, PPE, leukopaenia, lymphopaenia, anaemia, thrombocytopaenia, stomatitis, fatigue, diarrhoea, vomiting, nausea, pyrexia, dyspnoea, and pneumonia. Less frequently reported severe adverse reactions included Pneumocystis jirovecii pneumonia, abdominal pain, and cytomegalovirus infection including cytomegalovirus chorioretinitis, asthenia, cardiac arrest, cardiac failure, cardiac failure congestive, pulmonary embolism, thrombophlebitis, venous thrombosis, anaphylactic reaction, anaphylactoid reaction, toxic epidermal necrolysis, and Stevens - Johnson syndrome.</p><p><u>Tabulated list of adverse reactions</u></p><p>Table 5 summarises the adverse drug reactions that occurred in patients receiving doxorubicin pegylated liposomal in 4,231 patients for the treatment of breast cancer, ovarian cancer, multiple myeloma, and AIDS-related KS. Post-marketing adverse reactions are also included, as indicated by &ldquo;<sup>b</sup>&rdquo;. Frequencies are defined as very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10), uncommon (&ge; 1/1,000 to &lt; 1/100), rare (&ge; 1/10,000 to &lt; 1/1,000), very rare (&lt; 1/10,000) and not known (frequency cannot be estimated from the available data). Within each frequency grouping, where relevant, adverse reactions are presented in order of decreasing seriousness.</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>Table 5: Adverse reactions in patients treated with doxorubicin pegylated liposomal</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Frequency All Grades</strong></p></td><td colspan="2" rowspan="2" style="vertical-align:top"><p><strong>Adverse Drug Reaction</strong></p></td><td>&nbsp;</td></tr><tr><td>&nbsp;</td></tr><tr><td rowspan="17" style="vertical-align:top"><p>Infections and infestations</p></td><td rowspan="14" style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>Sepsis</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Pneumonia</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Pneumocystis jirovecii pneumonia</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Cytomegalovirus infection including cytomegalovirus chorioretinitis</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Mycobacterium avium complex infection</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Candidiasis</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Herpes zoster</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Urinary tract infection</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Infection</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Upper respiratory tract infection</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Oral candidiasis</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Folliculitis</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Pharyngitis</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Nasopharyngitis</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>Herpes simplex</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Fungal infection</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td colspan="2" style="vertical-align:top"><p>Opportunistic infection (including&nbsp;<em>Aspergillus,</em>&nbsp;<em>Histoplasma</em>,</p><p><em>Isospora</em>,&nbsp;<em>Legionella</em>,&nbsp;<em>Microsporidium</em>,&nbsp;<em>Salmonella</em>,&nbsp;<em>Staphylococcus</em>,&nbsp;</p><p><em>Toxoplasma</em>,&nbsp;<em>Tuberculosis</em>)<sup>a</sup></p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Neoplasms benign, malignant and unspecified (including cysts and polyps)</p></td><td rowspan="3" style="vertical-align:top"><p>Not known</p></td><td colspan="2" style="vertical-align:top"><p>Acute myeloid leukaemia<sup>b</sup></p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Myelodysplastic syndrome<sup>b</sup></p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Oral neoplasm<sup>b</sup></p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="9" style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td rowspan="4" style="vertical-align:top"><p>Very common</p></td><td colspan="2" style="vertical-align:top"><p>Leukopaenia</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Neutropaenia</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Lymphopaenia</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Anaemia (including hypochromic)</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>Thrombocytopaenia</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Febrile neutropaenia</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>Pancytopaenia</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Thrombocytosis</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td colspan="2" style="vertical-align:top"><p>Bone marrow failure</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Immune system disorders</p></td><td rowspan="2" style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>Hypersensitivity</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Anaphylactic reaction</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td colspan="2" style="vertical-align:top"><p>Anaphylactoid reaction</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="8" style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td colspan="2" style="vertical-align:top"><p>Decreased appetite</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>Cachexia</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Dehydration</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Hypokalaemia</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Hyponatraemia</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Hypocalcaemia</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>Hyperkalaemia</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Hypomagnesaemia</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Psychiatric disorders</p></td><td rowspan="4" style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>Confusional state</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Anxiety</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Depression</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Insomnia</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="14" style="vertical-align:top"><p>Nervous system disorders</p></td><td rowspan="9" style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>Neuropathy peripheral</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Peripheral sensory neuropathy</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Neuralgia</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Paraesthesia</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Hypoaesthesia</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Dysgeusia</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Headache</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Lethargy</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Dizziness</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>Polyneuropathy</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Convulsion</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Syncope</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Dysaesthesia</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Somnolence</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>Conjunctivitis</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>Vision blurred</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Lacrimation increased</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td colspan="2" style="vertical-align:top"><p>Retinitis</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="12" style="vertical-align:top"><p>Cardiac disorders<sup>a</sup></p></td><td style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>Tachycardia</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="6" style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>Palpitations</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Cardiac arrest</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Cardiac failure</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Cardiac failure congestive</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Cardiomyopathy</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Cardiotoxicity</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>Rare</p></td><td colspan="2" style="vertical-align:top"><p>Ventricular arrhythmia</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Bundle branch block right</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Conduction disorder</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Atrioventricular block</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Cyanosis</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="10" style="vertical-align:top"><p>Vascular disorders</p></td><td rowspan="3" style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>Hypertension</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Hypotension</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Flushing</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>Pulmonary embolism</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Infusion site necrosis (including soft tissue necrosis and skin necrosis)</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Phlebitis</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Orthostatic hypotension</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Rare</p></td><td colspan="2" style="vertical-align:top"><p>Thrombophlebitis</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Venous thrombosis</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Vasodilatation</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="7" style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td rowspan="4" style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>Dyspnoea</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Dyspnoea exertional</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Epistaxis</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Cough</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>Asthma</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Chest discomfort</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td colspan="2" style="vertical-align:top"><p>Throat tightness</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="19" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td rowspan="5" style="vertical-align:top"><p>Very common</p></td><td colspan="2" style="vertical-align:top"><p>Stomatitis</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Nausea</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Vomiting</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Diarrhoea</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Constipation</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="10" style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>Gastritis</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Aphthous stomatitis</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Mouth ulceration</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Dyspepsia</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Dysphagia</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Oesophagitis</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Abdominal pain</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Abdominal pain upper</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Oral pain</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Dry mouth</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>Flatulence</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Gingivitis</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Rare</p></td><td colspan="2" style="vertical-align:top"><p>Glossitis</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Lip ulceration</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="25" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td rowspan="3" style="vertical-align:top"><p>Very common</p></td><td colspan="2" style="vertical-align:top"><p>Palmar plantar erythrodysaesthesia syndrome<sup>a</sup></p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Rash (including erythematous, maculo-papular, and papular)</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Alopecia</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="7" style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>Skin exfoliation</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Blister</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Dry skin</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Erythema</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Pruritus</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Hyperhidrosis</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Skin hyperpigmentation</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="10" style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>Dermatitis</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Dermatitis exfoliative</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Acne</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Skin ulcer</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Dermatitis allergic</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Urticaria</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Skin discolouration</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Petechiae</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Pigmentation disorder</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Nail disorder</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Rare</p></td><td colspan="2" style="vertical-align:top"><p>Toxic epidermal necrolysis</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Erythema multiforme</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Dermatitis bullous</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Lichenoid keratosis</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td colspan="2" style="vertical-align:top"><p>Stevens-Johnson syndrome<sup>b</sup></p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="6" style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td colspan="2" style="vertical-align:top"><p>Musculoskeletal pain (including musculoskeletal chest pain, back pain, pain in extremity)</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>Muscle spasms</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Myalgia</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Arthralgia</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Bone pain</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>Muscular weakness</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>Dysuria</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Reproductive disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>Breast pain</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Rare</p></td><td colspan="2" style="vertical-align:top"><p>Vaginal infection</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Scrotal erythema</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="17" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td rowspan="2" style="vertical-align:top"><p>Very common</p></td><td colspan="2" style="vertical-align:top"><p>Pyrexia</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Fatigue</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="10" style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>Infusion-related reaction</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Pain</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Chest pain</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Influenza-like illness</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Chills</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Mucosal inflammation</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Asthenia</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Malaise</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Oedema</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Oedema peripheral</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>Administration site extravasation</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Injection site reaction</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Face oedema</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Hyperthermia</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td colspan="2" style="vertical-align:top"><p>Mucous membrane disorder</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>Weight decreased</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>Ejection fraction decreased</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Rare</p></td><td colspan="2" style="vertical-align:top"><p>Liver function test abnormal (including Blood bilirubin increased, Alanine aminotransferase increased and Aspartate aminotransferase increased)</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Blood creatinine increased</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Injury, poisoning and procedural complications</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>Radiation recall phenomenon<sup>a</sup></p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>a</sup>&nbsp;See&nbsp;<u>Description of selected adverse reactions</u></p><p><sup>b</sup>&nbsp;Post-marketing adverse reaction</p></td><td style="vertical-align:top">&nbsp;</td><td><p>&nbsp;</p></td></tr></tbody></table><p><u>Description of selected adverse reactions</u></p><p><em><u>Palmar plantar erythrodysaesthesia</u></em></p><p>The most common undesirable effect reported in breast/ovarian clinical trials was palmar-plantar erythrodysesthesia (PPE). The overall incidence of PPE reported was 41.3% and 51.1% in the ovarian and breast clinical trials, respectively. These effects were mostly mild, with severe (grade 3) cases reported in 16.3% and 19.6% of patients. The reported incidence of life-threatening (grade 4) cases was &lt; 1%. PPE infrequently resulted in permanent treatment discontinuation (1.9% and 10.8%). PPE was reported in 16% of multiple myeloma patients treated with doxorubicin pegylated liposomal plus bortezomib combination therapy. Grade 3 PPE was reported in 5% of patients. No grade 4 PPE was reported. The rate of PPE was substantially lower in the AIDS-KS population (1.3% all grade, 0.4% grade 3 PPE, no grade 4 PPE).</p><p><em><u>Opportunistic infections</u></em></p><p>Respiratory undesirable effects commonly occurred in clinical studies of doxorubicin pegylated liposomal and may be related to opportunistic infections (OI&#39;s) in the AIDS population. Opportunistic infections are observed in KS patients after administration with doxorubicin pegylated liposomal, and are frequently observed in patients with HIV induced immunodeficiency. The most frequently observed OI&#39;s in clinical studies were candidiasis, cytomegalovirus, herpes simplex, Pneumocystis jirovecii pneumonia, and mycobacterium avium complex.</p><p><em><u>Cardiac toxicity</u></em></p><p>An increased incidence of congestive heart failure is associated with doxorubicin therapy at cumulative lifetime doses &gt; 450 mg/m<sup>2</sup>&nbsp;or at lower doses for patients with cardiac risk factors. Endomyocardial biopsies on nine of ten AIDS-KS patients receiving cumulative doses of doxorubicin pegylated liposomal greater than 460 mg/m<sup>2</sup>&nbsp;indicate no evidence of anthracycline-induced cardiomyopathy. The recommended dose of doxorubicin pegylated liposomal for AIDS-KS patients is 20 mg/m<sup>2</sup>&nbsp;every two-to-three weeks. The cumulative dose at which cardiotoxicity would become a concern for these AIDS-KS patients (&gt; 400 mg/m<sup>2</sup>) would require more than 20 courses of doxorubicin pegylated liposomal therapy over 40 to 60 weeks.</p><p>In addition, endomyocardial biopsies were performed in 8 solid tumour patients with cumulative anthracycline doses of 509 mg/m<sup>2</sup>&ndash;1,680 mg/m<sup>2</sup>. The range of Billingham cardiotoxicity scores was grades 0-1.5. These grading scores are consistent with no or mild cardiac toxicity.</p><p>In the pivotal phase III trial versus doxorubicin, 58/509 (11.4%) randomised subjects (10 treated with doxorubicin pegylated liposomal at a dose of 50 mg/m<sup>2</sup>/every 4 weeks versus 48 treated with doxorubicin at a dose of 60 mg/m<sup>2</sup>/every 3 weeks) met the protocol-defined criteria for cardiac toxicity during treatment and/or follow-up. Cardiac toxicity was defined as a decrease of 20 points or greater from baseline if the resting LVEF remained in the normal range or a decrease of 10 points or greater if the LVEF became abnormal (less than the lower limit for normal). None of the 10 doxorubicin pegylated liposomal subjects who had cardiac toxicity by LVEF criteria developed signs and symptoms of CHF. In contrast, 10 of 48 doxorubicin subjects who had cardiac toxicity by LVEF criteria also developed signs and symptoms of CHF.</p><p>In patients with solid tumours, including a subset of patients with breast and ovarian cancers, treated at a dose of 50 mg/m<sup>2</sup>/cycle with lifetime cumulative anthracycline doses up to 1,532 mg/m<sup>2</sup>, the incidence of clinically significant cardiac dysfunction was low. Of the 418 patients treated with doxorubicin pegylated liposomal 50 mg/m<sup>2</sup>/cycle, and having a baseline measurement of left ventricular ejection fraction (LVEF) and at least one follow-up measurement assessed by MUGA scan, 88 patients had a cumulative anthracycline dose of &gt; 400 mg/m<sup>2</sup>, an exposure level associated with an increased risk of cardiovascular toxicity with conventional doxorubicin. Only 13 of these 88 patients (15%) had at least one clinically significant change in their LVEF, defined as an LVEF value less than 45% or a decrease of at least 20 points from baseline. Furthermore, only 1 patient (cumulative anthracycline dose of 944 mg/m<sup>2</sup>), discontinued study treatment because of clinical symptoms of congestive heart failure.</p><p><em><u>Radiation recall phenomenon</u></em></p><p>Recall of skin reaction due to prior radiotherapy has occurred uncommonly with doxorubicin pegylated liposomal administration.</p><p><u>To reports any side effect(s):</u></p><p><strong>Saudi Arabia:</strong></p><p><strong><img src="data:image/png;base64,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" alt="" width="536" height="100" vspace="0" hspace="0" border="0" style="width:536px;height:100px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></strong></p><p><strong>Other GCC States:</strong></p><p><strong><img src="data:image/png;base64,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" alt="" width="800" height="44" vspace="0" hspace="0" border="0" style="width:800px;height:44px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Acute overdosing with doxorubicin hydrochloride worsens the toxic effects of mucositis, leukopaenia and thrombocytopaenia. Treatment of acute overdose of the severely myelosuppressed patient consists of hospitalisation, antibiotics, platelet and granulocyte transfusions and symptomatic treatment of mucositis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Cytotoxic agents (anthracyclines and related substances), ATC code: L01DB01.</p><p><strong>&nbsp;Mechanism of action</strong></p><p>The active ingredient of doxorubicin hydrochloride liposome injection is doxorubicin hydrochloride. The exact mechanism of the antitumour activity of doxorubicin is not known. It is generally believed that inhibition of DNA, RNA and protein synthesis is responsible for the majority of the cytotoxic effects. This is probably the result of intercalation of the anthracycline between adjacent base pairs of the DNA double helix thus preventing their unwinding for replication.</p><p><u>Clinical efficacy and safety</u></p><p>A phase III randomised study of doxorubicin Hydrochloride Liposome versus doxorubicin in patients with metastatic breast cancer was completed in 509 patients. The protocol-specified objective of demonstrating non-inferiority between doxorubicin Hydrochloride Liposome and doxorubicin was met, the hazard ratio (HR) for progression-free survival (PFS) was 1.00 (95% CI for HR=0.82-1.22). The treatment HR for PFS when adjusted for prognostic variables was consistent with PFS for the ITT population.</p><p>The primary analysis of cardiac toxicity showed the risk of developing a cardiac event as a function of cumulative anthracycline dose was significantly lower with doxorubicin Hydrochloride Liposome than with doxorubicin (HR=3.16, p &lt; 0.001). At cumulative doses greater than 450 mg/m<sup>2</sup>&nbsp;there were no cardiac events with doxorubicin Hydrochloride Liposome.</p><p>A phase III comparative study of doxorubicin Hydrochloride Liposome versus topotecan in patients with epithelial ovarian cancer following the failure of first-line, platinum-based chemotherapy was completed in 474 patients. There was a benefit in overall survival (OS) for doxorubicin Hydrochloride Liposome-treated patients over topotecan-treated patients as indicated by a hazard ratio (HR) of 1.216 (95% CI: 1.000; 1.478), p=0.050. The survival rates at 1, 2 and 3 years were 56.3%, 34.7% and 20.2% respectively on doxorubicin Hydrochloride Liposome, compared to 54.0%, 23.6% and 13.2% on topotecan.</p><p>For the sub-group of patients with platinum-sensitive disease the difference was greater: HR of 1.432 (95% CI: 1.066; 1.923), p=0.017. The survival rates at 1, 2 and 3 years were 74.1%, 51.2% and 28.4% respectively on doxorubicin Hydrochloride Liposome, compared to 66.2%, 31.0% and 17.5% on topotecan.</p><p>The treatments were similar in the sub-group of patients with platinum-refractory disease: HR of 1.069 (95% CI: 0.823; 1.387), p=0.618. The survival rates at 1, 2 and 3 years were 41.5%, 21.1% and 13.8% respectively on doxorubicin Hydrochloride Liposome, compared to 43.2%, 17.2% and 9.5% on topotecan.</p><p>A phase III randomised, parallel-group, open-label, multicentre study comparing the safety and efficacy of doxorubicin Hydrochloride Liposome plus bortezomib combination therapy with bortezomib monotherapy in patients with multiple myeloma who have received at least 1 prior therapy and who did not progress while receiving anthracycline-based therapy, was conducted in 646 patients. There was a significant improvement in the primary endpoint of time to progression (TTP) for patients treated with combination therapy of doxorubicin Hydrochloride Liposome plus bortezomib compared to patients treated with bortezomib monotherapy as indicated by a risk reduction (RR) of 35% (95% CI: 21-47%), p &lt; 0.0001, based on 407 TTP events. The median TTP was 6.9 months for the bortezomib monotherapy patients compared with 8.9 months for the doxorubicin Hydrochloride Liposome plus bortezomib combination therapy patients. A protocol-defined interim analysis (based on 249 TTP events) triggered early study termination for efficacy. This interim analysis showed a TTP risk reduction of 45% (95% CI: 29-57%), p &lt; 0.0001. The median TTP was 6.5 months for the bortezomib monotherapy patients compared with 9.3 months for the doxorubicin Hydrochloride Liposome plus bortezomib combination therapy patients. These results, though not mature, constituted the protocol defined final analysis. The final analysis for overall survival (OS) performed after a median follow-up of 8.6 years showed no significant difference in OS between the two treatment arms. The median OS was 30.8 months (95% CI; 25.2-36.5 months) for the bortezomib monotherapy patients and 33.0 months (95% CI; 28.9-37.1 months) for the doxorubicin Hydrochloride Liposome plus bortezomib combination therapy patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Doxorubicin liposome is a long-circulating pegylated liposomal formulation of doxorubicin hydrochloride. Pegylated liposomes contain surface-grafted segments of the hydrophilic polymer methoxypolyethylene glycol (MPEG). These linear MPEG groups extend from the liposome surface creating a protective coating that reduces interactions between the lipid bilayer membrane and the plasma components. This allows the Doxorubicin liposomes to circulate for prolonged periods in the blood stream. Pegylated liposomes are small enough (average diameter of approximately 100 nm) to pass intact (extravasate) through defective blood vessels supplying tumours. Evidence of penetration of pegylated liposomes from blood vessels and their entry and accumulation in tumours has been seen in mice with C-26 colon carcinoma tumours and in transgenic mice with KS-like lesions. The pegylated liposomes also have a low permeability lipid matrix and internal aqueous buffer system that combine to keep doxorubicin hydrochloride encapsulated during liposome residence time in circulation.</p><p>The plasma pharmacokinetics of Doxorubicin liposomal in humans differ significantly from those reported in the literature for standard doxorubicin hydrochloride preparations. At lower doses (10 mg/m<sup>2</sup>&ndash;20 mg/m<sup>2</sup>) Doxorubicin liposomal displayed linear pharmacokinetics. Over the dose range of 10 mg/m<sup>2</sup>&ndash;60 mg/m<sup>2</sup>&nbsp;Doxorubicin liposomal displayed non-linear pharmacokinetics. Standard doxorubicin hydrochloride displays extensive tissue distribution (volume of distribution: 700 to 1,100 l/m<sup>2</sup>) and a rapid elimination clearance (24 to 73 l/h/m<sup>2</sup>). In contrast, the pharmacokinetic profile of Doxorubicin liposomal indicates that Doxorubicin liposomal &nbsp;is confined mostly to the vascular fluid volume and that the clearance of doxorubicin from the blood is dependent upon the liposomal carrier. Doxorubicin becomes available after the liposomes are extravasated and enter the tissue compartment.</p><p>At equivalent doses, the plasma concentration and AUC values of Doxorubicin liposomal which represent mostly doxorubicin hydrochloride (containing 90% to 95% of the measured doxorubicin) are significantly higher than those achieved with standard doxorubicin hydrochloride preparations.</p><p>Doxorubicin Hydrochloride Liposome should not be used interchangeably with other formulations of doxorubicin hydrochloride.</p><p><u>Population pharmacokinetics</u></p><p>The pharmacokinetics of Doxorubicin liposomal was evaluated in 120 patients from 10 different clinical trials using the population pharmacokinetic approach. The pharmacokinetics of Doxorubicin liposomal over the dose range of 10 mg/m<sup>2</sup>&nbsp;to 60 mg/m<sup>2</sup>&nbsp;was best described by a two compartment non-linear model with zero order input and Michaelis-Menten elimination. The mean intrinsic clearance of Doxorubicin liposomal was 0.030 l/h/m<sup>2</sup>&nbsp;(range 0.008 to 0.152 l/h/m<sup>2</sup>) and the mean central volume of distribution was 1.93 l/m<sup>2&nbsp;</sup>(range 0.96-3.85 l/m<sup>2</sup>) approximating the plasma volume. The apparent half-life ranged from 24-231 hours, with a mean of 73.9 hours.</p><p><u>Breast cancer patients</u></p><p>The pharmacokinetics of Doxorubicin liposomal determined in 18 patients with breast carcinoma were similar to the pharmacokinetics determined in the larger population of 120 patients with various cancers. The mean intrinsic clearance was 0.016 l/h/m<sup>2</sup>&nbsp;(range 0.008-0.027 l/h/m<sup>2</sup>), the mean central volume of distribution was 1.46 l/m<sup>2</sup>&nbsp;(range 1.10-1.64 l/m<sup>2</sup>). The mean apparent half-life was 71.5 hours (range 45.2-98.5 hours).</p><p><u>Ovarian cancer patients</u></p><p>The pharmacokinetics of Doxorubicin liposomal determined in 11 patients with ovarian carcinoma were similar to the pharmacokinetics determined in the larger population of 120 patients with various cancers. The mean intrinsic clearance was 0.021 l/h/m<sup>2</sup>&nbsp;(range 0.009&ndash;0.041 l/h/m<sup>2</sup>), the mean central volume of distribution was 1.95 l/m<sup>2</sup>&nbsp;(range 1.67&ndash;2.40 l/m<sup>2</sup>). The mean apparent half-life was 75.0 hours (range 36.1&ndash;125 hours).</p><p><u>AIDS-related KS patients</u></p><p>The plasma pharmacokinetics of Doxorubicin liposomal were evaluated in 23 patients with KS who received single doses of 20 mg/m<sup>2</sup>&nbsp;administered by a 30-minute infusion. The pharmacokinetic parameters of Doxorubicin liposomal (primarily representing pegylated liposomal doxorubicin hydrochloride and low levels of unencapsulated doxorubicin hydrochloride) observed after the 20 mg/m<sup>2</sup>&nbsp;doses are presented in Table 6.</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Table 6. Pharmacokinetic parameters in Doxorubicin-treated AIDS-KS patients</strong></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Mean&nbsp;<u>+</u>&nbsp;standard error</p></td></tr><tr><td style="vertical-align:top"><p>Parameter</p></td><td style="vertical-align:top"><p>20 mg/m<sup>2</sup>&nbsp;(n=23)</p></td></tr><tr><td style="vertical-align:top"><p>Maximum plasma concentration* (&micro;g/ml)</p><p>Plasma clearance (l/h/m<sup>2</sup>)</p><p>Volume of distribution (l/m<sup>2</sup>)</p><p>AUC (&micro;g/ml h)</p><p>&lambda;&nbsp;<sub>1&nbsp;</sub>half-life (hours)</p><p>&lambda;&nbsp;<sub>2&nbsp;</sub>half-life (hours)</p></td><td style="vertical-align:top"><p>8.34 &plusmn; 0.49</p><p>0.041 &plusmn; 0.004</p><p>2.72 &plusmn; 0.120</p><p>590.00 &plusmn; 58.7</p><p>5.2 &plusmn; 1.4</p><p>55.0 &plusmn; 4.8</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>* Measured at the end of a 30-minute infusion</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In repeat dose studies conducted in animals, the toxicity profile of doxorubicin pegylated liposomal very similar to that reported in humans who receive long-term infusions of standard doxorubicin hydrochloride. With doxorubicin pegylated liposomal, the encapsulation of doxorubicin hydrochloride in pegylated liposomes results in these effects having a differing strength, as follows.</p><p><u>Cardiotoxicity</u></p><p>Studies in rabbits have shown that the cardiotoxicity of doxorubicin pegylated liposomal is reduced compared with conventional doxorubicin hydrochloride preparations.</p><p><u>Dermal toxicity</u></p><p>In studies performed after the repeated administration of doxorubicin pegylated liposomal to rats and dogs, serious dermal inflammations and ulcer formations were observed at clinically relevant dosages. In the study in dogs, the occurrence and severity of these lesions was reduced by lowering the dose or prolonging the intervals between doses. Similar dermal lesions, which are described as palmar-plantar erythrodysesthesia were also observed in patients after long-term intravenous infusion (see section 4.8).</p><p><u>Anaphylactoid response</u></p><p>During repeat dose toxicology studies in dogs, an acute response characterised by hypotension, pale mucous membranes, salivation, emesis and periods of hyperactivity followed by hypoactivity and lethargy was observed following administration of pegylated liposomes (placebo). A similar, but less severe response was also noted in dogs treated with doxorubicin pegylated liposomal and standard doxorubicin.</p><p>The hypotensive response was reduced in magnitude by pretreatment with antihistamines. However, the response was not life-threatening and the dogs recovered quickly upon discontinuation of treatment.</p><p>Local toxicity</p><p>Subcutaneous tolerance studies indicate that doxorubicin pegylated liposomal, as against standard doxorubicin hydrochloride, causes slighter local irritation or damage to the tissue after a possible extravasation.</p><p>Mutagenicity and carcinogenicity</p><p>Although no studies have been conducted with doxorubicin pegylated liposomal, doxorubicin hydrochloride, the pharmacologically active ingredient of doxorubicin pegylated liposomal, is mutagenic and carcinogenic. Pegylated placebo liposomes are neither mutagenic nor genotoxic.</p><p>Reproductive toxicity</p><p>doxorubicin pegylated liposomal resulted in mild to moderate ovarian and testicular atrophy in mice after a single dose of 36 mg/kg. Decreased testicular weights and hypospermia were present in rats after repeat doses &ge; 0.25 mg/kg/day and diffuse degeneration of the seminiferous tubules and a marked decrease in spermatogenesis were observed in dogs after repeat doses of 1 mg/kg/day (see section 4.6).</p><p>Nephrotoxicity</p><p>A study has shown that doxorubicin pegylated liposomal at a single intravenous dose of over twice the clinical dose produces renal toxicity in monkeys. Renal toxicity has been observed with even lower single doses of doxorubicin HCl in rats and rabbits. Since an evaluation of the post-marketing safety database for doxorubicin pegylated liposomal in patients has not suggested a significant nephrotoxicity liability of doxorubicin pegylated liposomal, these findings in monkeys may not have relevance to patient risk assessment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &alpha;-(2-[1,2-distearoyl-sn-glycero(3)phosphooxy]ethylcarbamoyl)-&omega;-methoxypoly(oxyethylen) -40 sodium salt (MPEG-DSPE)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fully hydrogenated soy phosphatidylcholine (HSPC)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cholesterol</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ammonium sulfate</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sucrose</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Histidine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Water for injections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hydrochloric acid (for ph adjustment)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sodium hydroxide (for ph adjustment</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                18 months.
After dilution:
•	Chemical and physical in-use stability has been demonstrated for 24 hours at 2°C to 8°C.
•	From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and should not be longer than 24 hours at 2°C to 8°C.
•	Partially used vials must be discarded.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&deg;C - 8&deg;C). Do not freeze. Store in the original package in order to protect from light.</p><p>For storage conditions of the diluted medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>10 ml/20mm Type I transparent tubular glass vial stoppered with 20mm grey bromobutyl rubber stopper and sealed with 20 mm flip off seal.</p><p>Supplied as a single pack.</p><p>30 mL/20mm USP Type I transparent tubular glass vial stoppered with 20mm grey bromobutyl rubber stopper and sealed with 20 mm flip off seal.</p><p>Supplied as a single pack.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not use material that shows evidence of precipitation or any other particulate matter.</p><p>Caution must be exercised in handling Doxorubicin Liposomal solution. The use of gloves is</p><p>required.</p><p>If Doxorubicin Liposomal comes into contact with skin or mucosa, wash immediately and</p><p>thoroughly with soap and water. Doxorubicin Liposomal must be handled and disposed of in a manner consistent with that of other anticancer medicinal products in accordance with local</p><p>requirements.</p><p>Determine the dose of Doxorubicin Liposomal to be administered (based upon the recommended dose and the patient&rsquo;s body surface area). Take the appropriate volume of Doxorubicin Liposomal up into a sterile syringe. Aseptic technique must be strictly observed since no preservative or bacteriostatic agent is present in Doxorubicin Liposomal. The appropriate dose of Doxorubicin Liposomal must be diluted in 5% (50 mg/ml) glucose solution for infusion prior to administration.&nbsp; For doses &lt; 90 mg, dilute Doxorubicin Liposomal in 250 ml, and for doses &ge; 90 mg, dilute Doxorubicin Liposomal in 500 ml. This can be infused over 60 or 90 minutes as detailed in 4.2.</p><p>The use of any diluent other than 5% (50 mg/ml) glucose solution for infusion, or the presence of any bacteriostatic agent such as benzyl alcohol may cause precipitation of Doxorubicin Liposomal.</p><p>It is recommended that the Doxorubicin Liposomal infusion line be connected through the side port of an intravenous infusion of 5% (50 mg/ml) glucose. Infusion may be given through a peripheral vein. Do not use with in-line filters.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sudair Pharma Company (SPC)
King Fahad Road, building 8006- 4th Floor Riyadh, Saudi Arabia
Tel: +966-11-920001432
Fax: +966-11-4668195
Email: info@sudairpharma.com
Mailing: P.O. Box 12363 Riyadh, Saudi Arabia
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                03/2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>